Net revenue of $70.8 million in Q3 2024 driven by 30% increase in UDENYCA® net revenue, quarter-over-quarter – – UDENYCA labeling and pac ...

Developing a vaccination program for infectious bursal disease virus (IBDV) challenges should consider the severity and ...

Q3 2024 Earnings Call Transcript November 6, 2024 Coherus BioSciences, Inc. beats earnings expectations. Reported EPS is $-0.01, expectations were $-0.1. Operator: Good day, and thank you for standing ...

A central question in adult stem cell biology is elucidating the signaling pathways regulating their dynamics and function in diverse physiological and age-related contexts. Muscle stem cells in ...

Antibody proteomics advances vaccine research, revealing immune responses and identifying proteins essential for developing effective vaccines against diseases.

School of Life Sciences, Zhengzhou University, Zhengzhou 450001, People’s Republic of China Longhu Laboratory, Zhengzhou 450046, People’s Republic of China School of Life Sciences, Zhengzhou ...

Hope Center for Neurological Disorders, Washington University School of Medicine, St. Louis, USA ...

Net income: The net income attributable to Serina for the three months ended September 30, 2024 was $1.4 million, or $0.16 per share (basic) and $0.13 per share (diluted) compared to net income of ...

Serina Therapeutics, Inc. ("Serina") (NYSE American: SER), a clinical-stage biotechnology company advancing its lead IND candidate SER-252 for advanced Parkinson's ...

Serina’s POZ Platform TM provides the potential to improve the integrated efficacy and safety profile of multiple modalities including small molecules, RNA-based therapeutics and antibody-based ...

Another key priority for our anti-myostatin platform is advancing our novel selective anti-myostatin antibody SRK-439 ... And, of course, more to come, but frankly from FDA's labeling approach, they ...